Prevention of hip fractures by exposure to sunlight and pharmacotherapy in patients with Alzheimer's disease

Jun Iwamoto, Yoshihiro Sato, Kiyoshi Tanaka, Tsuyoshi Takeda, Hideo Matsumoto

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Background and aims: Hypovitaminosis D and K due to malnutrition or sunlight deprivation, compensatory hyperparathyroidism, increased bone resorption, low bone mineral density (BMD), and an increased risk of falls may contribute to an increased risk of hip fractures in patients with Alzheimer's disease. The purpose of the present study was to clarify the efficacy of interventions against hip fractures in patients with Alzheimer's disease. Methods: With respect to randomized controlled trials (RCTs) regarding Alzheimer's disease and hip fractures, the literature was searched with PubMed. Results: Three RCTs were identified, and the relative risk (RR) and 95% confidence interval (CI) were calculated for individual RCTs. Exposure to sunlight with calcium supplementation, menatetrenone (vitamin K2) plus calcium and vitamin D supplementation, and risedronate plus calcium and vitamin D supplementation improved hypovitaminosis D and hyperparathyroidism, contributing to a reduction in bone resorption. Risedronate itself strongly decreased bone resorption. Menatetrenone also decreased the serum level of undercarboxylated osteocalcin. The three interventions increased metacarpal BMD and reduced the incidence of hip fractures. The respective RRs (95% CI) were 0.22 (0.049-0.999), 0.13 (0.031-0.554), and 0.26 (0.100-0.690). Conclusions: The present study clarified the efficacy of three interventions, including exposure to sunlight, menatetrenone, and risedronate with calcium and/or vitamin D supplementation against hip fractures in patients with Alzheimer's disease.

Original languageEnglish
Pages (from-to)277-281
Number of pages5
JournalAging clinical and experimental research
Volume21
Issue number4-5
Publication statusPublished - 2009 Aug

Fingerprint

Sunlight
Hip Fractures
Alzheimer Disease
Drug Therapy
Bone Resorption
Vitamin D
Calcium
Randomized Controlled Trials
Hyperparathyroidism
Bone Density
Confidence Intervals
Vitamin K 2
Metacarpal Bones
Osteocalcin
PubMed
Malnutrition
Incidence
Serum
menatetrenone
Risedronate Sodium

Keywords

  • Alzheimer's disease
  • Hip fracture
  • Mortality
  • Vitamin D
  • Vitamin K

ASJC Scopus subject areas

  • Ageing
  • Geriatrics and Gerontology

Cite this

Prevention of hip fractures by exposure to sunlight and pharmacotherapy in patients with Alzheimer's disease. / Iwamoto, Jun; Sato, Yoshihiro; Tanaka, Kiyoshi; Takeda, Tsuyoshi; Matsumoto, Hideo.

In: Aging clinical and experimental research, Vol. 21, No. 4-5, 08.2009, p. 277-281.

Research output: Contribution to journalArticle

Iwamoto, J, Sato, Y, Tanaka, K, Takeda, T & Matsumoto, H 2009, 'Prevention of hip fractures by exposure to sunlight and pharmacotherapy in patients with Alzheimer's disease', Aging clinical and experimental research, vol. 21, no. 4-5, pp. 277-281.
Iwamoto, Jun ; Sato, Yoshihiro ; Tanaka, Kiyoshi ; Takeda, Tsuyoshi ; Matsumoto, Hideo. / Prevention of hip fractures by exposure to sunlight and pharmacotherapy in patients with Alzheimer's disease. In: Aging clinical and experimental research. 2009 ; Vol. 21, No. 4-5. pp. 277-281.
@article{11e2230a5a7b42efb6af2d8fcbdd6e52,
title = "Prevention of hip fractures by exposure to sunlight and pharmacotherapy in patients with Alzheimer's disease",
abstract = "Background and aims: Hypovitaminosis D and K due to malnutrition or sunlight deprivation, compensatory hyperparathyroidism, increased bone resorption, low bone mineral density (BMD), and an increased risk of falls may contribute to an increased risk of hip fractures in patients with Alzheimer's disease. The purpose of the present study was to clarify the efficacy of interventions against hip fractures in patients with Alzheimer's disease. Methods: With respect to randomized controlled trials (RCTs) regarding Alzheimer's disease and hip fractures, the literature was searched with PubMed. Results: Three RCTs were identified, and the relative risk (RR) and 95{\%} confidence interval (CI) were calculated for individual RCTs. Exposure to sunlight with calcium supplementation, menatetrenone (vitamin K2) plus calcium and vitamin D supplementation, and risedronate plus calcium and vitamin D supplementation improved hypovitaminosis D and hyperparathyroidism, contributing to a reduction in bone resorption. Risedronate itself strongly decreased bone resorption. Menatetrenone also decreased the serum level of undercarboxylated osteocalcin. The three interventions increased metacarpal BMD and reduced the incidence of hip fractures. The respective RRs (95{\%} CI) were 0.22 (0.049-0.999), 0.13 (0.031-0.554), and 0.26 (0.100-0.690). Conclusions: The present study clarified the efficacy of three interventions, including exposure to sunlight, menatetrenone, and risedronate with calcium and/or vitamin D supplementation against hip fractures in patients with Alzheimer's disease.",
keywords = "Alzheimer's disease, Hip fracture, Mortality, Vitamin D, Vitamin K",
author = "Jun Iwamoto and Yoshihiro Sato and Kiyoshi Tanaka and Tsuyoshi Takeda and Hideo Matsumoto",
year = "2009",
month = "8",
language = "English",
volume = "21",
pages = "277--281",
journal = "Aging clinical and experimental research",
issn = "1594-0667",
publisher = "Springer Verlag",
number = "4-5",

}

TY - JOUR

T1 - Prevention of hip fractures by exposure to sunlight and pharmacotherapy in patients with Alzheimer's disease

AU - Iwamoto, Jun

AU - Sato, Yoshihiro

AU - Tanaka, Kiyoshi

AU - Takeda, Tsuyoshi

AU - Matsumoto, Hideo

PY - 2009/8

Y1 - 2009/8

N2 - Background and aims: Hypovitaminosis D and K due to malnutrition or sunlight deprivation, compensatory hyperparathyroidism, increased bone resorption, low bone mineral density (BMD), and an increased risk of falls may contribute to an increased risk of hip fractures in patients with Alzheimer's disease. The purpose of the present study was to clarify the efficacy of interventions against hip fractures in patients with Alzheimer's disease. Methods: With respect to randomized controlled trials (RCTs) regarding Alzheimer's disease and hip fractures, the literature was searched with PubMed. Results: Three RCTs were identified, and the relative risk (RR) and 95% confidence interval (CI) were calculated for individual RCTs. Exposure to sunlight with calcium supplementation, menatetrenone (vitamin K2) plus calcium and vitamin D supplementation, and risedronate plus calcium and vitamin D supplementation improved hypovitaminosis D and hyperparathyroidism, contributing to a reduction in bone resorption. Risedronate itself strongly decreased bone resorption. Menatetrenone also decreased the serum level of undercarboxylated osteocalcin. The three interventions increased metacarpal BMD and reduced the incidence of hip fractures. The respective RRs (95% CI) were 0.22 (0.049-0.999), 0.13 (0.031-0.554), and 0.26 (0.100-0.690). Conclusions: The present study clarified the efficacy of three interventions, including exposure to sunlight, menatetrenone, and risedronate with calcium and/or vitamin D supplementation against hip fractures in patients with Alzheimer's disease.

AB - Background and aims: Hypovitaminosis D and K due to malnutrition or sunlight deprivation, compensatory hyperparathyroidism, increased bone resorption, low bone mineral density (BMD), and an increased risk of falls may contribute to an increased risk of hip fractures in patients with Alzheimer's disease. The purpose of the present study was to clarify the efficacy of interventions against hip fractures in patients with Alzheimer's disease. Methods: With respect to randomized controlled trials (RCTs) regarding Alzheimer's disease and hip fractures, the literature was searched with PubMed. Results: Three RCTs were identified, and the relative risk (RR) and 95% confidence interval (CI) were calculated for individual RCTs. Exposure to sunlight with calcium supplementation, menatetrenone (vitamin K2) plus calcium and vitamin D supplementation, and risedronate plus calcium and vitamin D supplementation improved hypovitaminosis D and hyperparathyroidism, contributing to a reduction in bone resorption. Risedronate itself strongly decreased bone resorption. Menatetrenone also decreased the serum level of undercarboxylated osteocalcin. The three interventions increased metacarpal BMD and reduced the incidence of hip fractures. The respective RRs (95% CI) were 0.22 (0.049-0.999), 0.13 (0.031-0.554), and 0.26 (0.100-0.690). Conclusions: The present study clarified the efficacy of three interventions, including exposure to sunlight, menatetrenone, and risedronate with calcium and/or vitamin D supplementation against hip fractures in patients with Alzheimer's disease.

KW - Alzheimer's disease

KW - Hip fracture

KW - Mortality

KW - Vitamin D

KW - Vitamin K

UR - http://www.scopus.com/inward/record.url?scp=73849138165&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=73849138165&partnerID=8YFLogxK

M3 - Article

C2 - 19959915

AN - SCOPUS:73849138165

VL - 21

SP - 277

EP - 281

JO - Aging clinical and experimental research

JF - Aging clinical and experimental research

SN - 1594-0667

IS - 4-5

ER -